Eikon Therapeutics, Inc.

EIKN·NasdaqGS·Healthcare
Compare
6.39+0.84 (+15.14%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close5.55
Open5.69
Day range5.366.42
52-week range5.0117.40
Off day high−0.47%
Off 52-week high−63.28%
Volume658.57K
Avg. volume (3M)572.48K
Market cap346.11M
EPS (TTM)-8.51
Forward P/E-0.95
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding54.17M
Short interest15.62% of float
Earnings dateAug 13, 2026 (est.)
Analyst target24.33
Profit margin0.00%

Against its peers

Compare in full ›
EIKN AVBP OLMA CCCC ORIC 2410.HK
Market cap 346.11M 665.16M 659.73M 383.84M 968.12M 1.21B
P/E (TTM) — — — — — —
Forward P/E -1.0 -3.6 -2.9 -3.4 -5.5 -6.1
Price/book 0.7 1.8 1.5 1.6 2.5 4.0
Dividend yield — — — — — —
1-year change −57.40% −26.64% −7.94% +31.09% −25.58% −80.24%
Today +15.14% +3.61% +2.59% −2.80% −2.61% +9.61%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All EIKN news ›
Morningstar··2 outletsPositive

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

BOULDER, Colo., Oct. 8, 2026 – Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% – – EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026 –…

More from 1 other outlet
markets.businessinsider.com·Positive

Eikon Therapeutics submits EIK1006 IND application to FDA

Eikon Therapeutics (EIKN) announced the submission of an Investigational New Drug, or IND, application to the FDA to evaluate EIK1006 for the tr... Eikon Therapeutics submits EIK1006 IND application to FDA Eikon Therapeutics (EIKN)…

From the 4Search news index, newest first.

In the news

11mentions in 30 days
11with it in the headline
Mixedsentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance